EGFR and non-small cell lung carcinoma: Nonetheless, in the context of NSCLC, this limitation appears insignificant, given that NSCLC predominantly involves oncogenic driver mutations, notably KRAS (29%), EGFR (19%), BRAF (5%), HER2 (3%), MET (3%), ALK (3%), RET (1%), and ROS1 (1%) mutations [23].